LI
LGND icon

LRI Investments’s Ligand Pharmaceuticals LGND Stock Holding History

LRI Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85K Sell
9
-41
-82% -$9.66K ﹤0.01% 1222
2026
Q1 		$9.98K Hold
50
– – ﹤0.01% 888
2025
Q4 		$9.49K Sell
50
-7
-12% -$1.34K ﹤0.01% 881
2025
Q3 		$10K Hold
57
– – ﹤0.01% 875
2025
Q2 		$6.42K Hold
57
– – ﹤0.01% 949
2025
Q1 		$5.94K Hold
57
– – ﹤0.01% 901
2024
Q4 		$6.05K Hold
57
– – ﹤0.01% 886
2024
Q3 		$6.52K Hold
57
– – ﹤0.01% 876
2024
Q2 		$4.76K Buy
+57
New +$4.54K ﹤0.01% 905

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LRI Investments's LGND Position: Q2 2026 in Review

LRI Investments reduced its Ligand Pharmaceuticals (LGND) stake by 82% in Q2 2026, selling an estimated $9.66K and leaving 9 shares worth $2.85K. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

LRI Investments first reported a position in LGND in Q2 2024 and has held it in 9 quarters since. The position peaked at $10K in Q3 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • LRI Investments held 9 shares of Ligand Pharmaceuticals worth $2.85K as of Q2 2026.
  • LRI Investments sold 41 Ligand Pharmaceuticals shares in Q2 2026, an estimated $9.66K.
  • Ligand Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1222 holding.
  • LRI Investments first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • LRI Investments's Ligand Pharmaceuticals position peaked at $10K in Q3 2025.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.